Serum Lipids and Prostate Cancer

Detalhes bibliográficos
Autor(a) principal: Garrido, M
Data de Publicação: 2021
Outros Autores: Marta, J, Ribeiro, R, Campos Pinheiro, L, Guimarães, J
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10400.17/4030
Resumo: Background: Conflicting results are found in the literature relating serum lipids levels and prostate cancer. Some results imply a relationship between them; others contradict this association. The purpose of this study was to investigate a possible association between serum lipids levels and prostate cancer, at time of diagnosis. Methods: We measured serum levels of total cholesterol, HDL cholesterol, LDL cholesterol, and triglycerides in 237 patients submitted to a prostate biopsy, with PSA between 2 and 10 ng/ml. Patients without cancer at biopsy were used as controls, and the others were considered as cases. No information about lipid-lowering therapy, including statins, was available neither in cases nor in controls. Cases were divided into risk groups, according to the disease severity, based on staging. Lipids levels were compared between groups, using parametric and nonparametric tests. Logistic regression analysis and odds ratios were calculated. Results: LDL and total cholesterol levels were lower in patients with cancer, with the difference being statistically significant for LDL cholesterol (p = 0.010) and borderline for total cholesterol (p = 0.050). No significant differences were found between the several risk groups. Odds ratios for low LDL cholesterol (<130 mg/dl) and low total cholesterol (<200 mg/dl), with prostate cancer as the outcome, were 1.983 and 1.703, respectively. There were no significant differences between cases and controls for the other lipids. Conclusion: Lower LDL cholesterol (<130 mg/dl) and lower total cholesterol (<200 mg/dl) serum levels seem to associate with prostate cancer, at time of diagnosis.
id RCAP_03571ad885978a3c3022f51c0ccccb43
oai_identifier_str oai:repositorio.chlc.min-saude.pt:10400.17/4030
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Serum Lipids and Prostate CancerCHLC PAT CLINCHLC UROAgedMaleMiddle AgedCase-Control StudiesHumansCholesterol, LDL / bloodLipids / blood*Logistic ModelsOdds RatioProstatic Neoplasms / blood*Risk FactorsTriglycerides / bloodBackground: Conflicting results are found in the literature relating serum lipids levels and prostate cancer. Some results imply a relationship between them; others contradict this association. The purpose of this study was to investigate a possible association between serum lipids levels and prostate cancer, at time of diagnosis. Methods: We measured serum levels of total cholesterol, HDL cholesterol, LDL cholesterol, and triglycerides in 237 patients submitted to a prostate biopsy, with PSA between 2 and 10 ng/ml. Patients without cancer at biopsy were used as controls, and the others were considered as cases. No information about lipid-lowering therapy, including statins, was available neither in cases nor in controls. Cases were divided into risk groups, according to the disease severity, based on staging. Lipids levels were compared between groups, using parametric and nonparametric tests. Logistic regression analysis and odds ratios were calculated. Results: LDL and total cholesterol levels were lower in patients with cancer, with the difference being statistically significant for LDL cholesterol (p = 0.010) and borderline for total cholesterol (p = 0.050). No significant differences were found between the several risk groups. Odds ratios for low LDL cholesterol (<130 mg/dl) and low total cholesterol (<200 mg/dl), with prostate cancer as the outcome, were 1.983 and 1.703, respectively. There were no significant differences between cases and controls for the other lipids. Conclusion: Lower LDL cholesterol (<130 mg/dl) and lower total cholesterol (<200 mg/dl) serum levels seem to associate with prostate cancer, at time of diagnosis.WileyRepositório do Centro Hospitalar Universitário de Lisboa Central, EPEGarrido, MMarta, JRibeiro, RCampos Pinheiro, LGuimarães, J2022-03-31T12:06:15Z20212021-01-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10400.17/4030engJ Clin Lab Anal. 2021 Apr;35(4):e23705.10.1002/jcla.23705.info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-03-10T09:44:59Zoai:repositorio.chlc.min-saude.pt:10400.17/4030Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T17:21:20.276964Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Serum Lipids and Prostate Cancer
title Serum Lipids and Prostate Cancer
spellingShingle Serum Lipids and Prostate Cancer
Garrido, M
CHLC PAT CLIN
CHLC URO
Aged
Male
Middle Aged
Case-Control Studies
Humans
Cholesterol, LDL / blood
Lipids / blood*
Logistic Models
Odds Ratio
Prostatic Neoplasms / blood*
Risk Factors
Triglycerides / blood
title_short Serum Lipids and Prostate Cancer
title_full Serum Lipids and Prostate Cancer
title_fullStr Serum Lipids and Prostate Cancer
title_full_unstemmed Serum Lipids and Prostate Cancer
title_sort Serum Lipids and Prostate Cancer
author Garrido, M
author_facet Garrido, M
Marta, J
Ribeiro, R
Campos Pinheiro, L
Guimarães, J
author_role author
author2 Marta, J
Ribeiro, R
Campos Pinheiro, L
Guimarães, J
author2_role author
author
author
author
dc.contributor.none.fl_str_mv Repositório do Centro Hospitalar Universitário de Lisboa Central, EPE
dc.contributor.author.fl_str_mv Garrido, M
Marta, J
Ribeiro, R
Campos Pinheiro, L
Guimarães, J
dc.subject.por.fl_str_mv CHLC PAT CLIN
CHLC URO
Aged
Male
Middle Aged
Case-Control Studies
Humans
Cholesterol, LDL / blood
Lipids / blood*
Logistic Models
Odds Ratio
Prostatic Neoplasms / blood*
Risk Factors
Triglycerides / blood
topic CHLC PAT CLIN
CHLC URO
Aged
Male
Middle Aged
Case-Control Studies
Humans
Cholesterol, LDL / blood
Lipids / blood*
Logistic Models
Odds Ratio
Prostatic Neoplasms / blood*
Risk Factors
Triglycerides / blood
description Background: Conflicting results are found in the literature relating serum lipids levels and prostate cancer. Some results imply a relationship between them; others contradict this association. The purpose of this study was to investigate a possible association between serum lipids levels and prostate cancer, at time of diagnosis. Methods: We measured serum levels of total cholesterol, HDL cholesterol, LDL cholesterol, and triglycerides in 237 patients submitted to a prostate biopsy, with PSA between 2 and 10 ng/ml. Patients without cancer at biopsy were used as controls, and the others were considered as cases. No information about lipid-lowering therapy, including statins, was available neither in cases nor in controls. Cases were divided into risk groups, according to the disease severity, based on staging. Lipids levels were compared between groups, using parametric and nonparametric tests. Logistic regression analysis and odds ratios were calculated. Results: LDL and total cholesterol levels were lower in patients with cancer, with the difference being statistically significant for LDL cholesterol (p = 0.010) and borderline for total cholesterol (p = 0.050). No significant differences were found between the several risk groups. Odds ratios for low LDL cholesterol (<130 mg/dl) and low total cholesterol (<200 mg/dl), with prostate cancer as the outcome, were 1.983 and 1.703, respectively. There were no significant differences between cases and controls for the other lipids. Conclusion: Lower LDL cholesterol (<130 mg/dl) and lower total cholesterol (<200 mg/dl) serum levels seem to associate with prostate cancer, at time of diagnosis.
publishDate 2021
dc.date.none.fl_str_mv 2021
2021-01-01T00:00:00Z
2022-03-31T12:06:15Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10400.17/4030
url http://hdl.handle.net/10400.17/4030
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv J Clin Lab Anal. 2021 Apr;35(4):e23705.
10.1002/jcla.23705.
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Wiley
publisher.none.fl_str_mv Wiley
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799131309296058368